Company Profile

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Employees

Sector

Biotechnology & Medical Research

More about the company

14/06	Menarini Group and Stemline Therapeutics, Inc. Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis	CI
28/05	The Menarini Group and Stemline Therapeutics, Inc. Presents New Data From The Phase 1b/2 ELEVATE Study Of Elacestrant In Combination With Capivasertib In Patients With ER+, HER2- Metastatic Breast Cancer	CI
25/05	Menarini Group Announces New Data At the American Society of Clinical Oncology 2026 Annual Meeting	CI
09/12	Menarini Group and Stemline Therapeutics, Inc. Presents Elacestrant Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium	CI
24/11	Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ELZONRIS	CI
20/25/20	Menarini Group and Stemline Therapeutics Inc. Announce Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm	CI
12/24/12	Menarini Group Along with Stemline Therapeutics, Inc and Medsir Present the Phase III Study Adela	CI
11/23/11	Menarini Group Presents Initial Safety and Efficacy Data from Phase 1B/2 Elevate and Electra Combination Studies of Orserdu® (Elacestrant) in Patients with Er+, Her2- Metastatic Breast Cancer At the 2023 San Antonio Breast Cancer Symposium	CI
08/23/08	Menarini Group and Stemline Therapeutics, Inc. Presents New Progression-Free Survival Data from Emerald Clinical Study of Orserdu (Elacestrant) in Clinically Relevant Subgroups of Patients with Esr1 Mutations At Sabcs 2023	CI
21/23/21	The Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ORSerDU	CI
30/23/30	Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group	CI
20/23/20	European Commission Approves Menarini Group?s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation	CI
26/23/26	The Menarini Group and Stemline Therapeutics Announce Results from A New Analysis of the Pivotal EMERALD Clinical Study	CI

17/20/17	Stemline Therapeutics : The Menarini Group received the coveted XV Transatlantic Award from the American Chamber of Commerce in Italy	AQ
10/20/10	STEMLINE THERAPEUTICS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/20/12	STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
05/20/05	Stemline Therapeutics : The Menarini Group signs the agreement for the acquisition of Stemline Therapeutics for a maximum consideration of $ 677 million	AQ
04/20/04	STEMLINE THERAPEUTICS INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

16/19/16	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
16/19/16	USA-Les valeurs à suivre à Wall Street (actualisé)

Manager	Title	Age	Since
Ivan Bergstein CEO	Chief Executive Officer	60	-
David Gionco DFI	Director of Finance/CFO	65	16/01/2014
Nassir Habboubi CTO	Chief Tech/Sci/R&D Officer	-	01/01/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/06/20	Ivan Bergstein	Free	Chief Executive Officer	38,72,092	7.3739%
10/06/20	Robert Francomano	Tender	Executive/Senior Manager	2,50,891	0.4778%
10/06/20	Ron Bentsur	Tender	Director	1,51,450	0.2884%

Stemline Therapeutics, Inc. Share Price

Stocks

US85858C1071

Biotechnology & Medical Research

Latest news: Stemline Therapeutics, Inc.

Press Releases: Stemline Therapeutics, Inc.

News in other languages: Stemline Therapeutics, Inc.

Managers and Directors: Stemline Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STEMLINE THERAPEUTICS, INC.	-.--%	-.--%	-	-	57Cr
WUXI APPTEC CO., LTD.	-0.37%	-3.67%	+57.21%	+87.75%	7.18TCr
ARGENX SE	+1.04%	-0.23%	+39.63%	+85.28%	6.01TCr
WUXI BIOLOGICS (CAYMAN) INC.	+0.19%	+1.61%	+35.10%	+17.20%	2.79TCr
INSMED INCORPORATED	-0.14%	-2.75%	-14.13%	+356.79%	2.57TCr
BIONTECH SE	+0.57%	+1.10%	+1.02%	-2.89%	2.49TCr
GENMAB A/S	+0.52%	+1.62%	+26.42%	-7.66%	2.09TCr
PHARMAESSENTIA CORPORATION	-1.70%	+0.43%	+150.24%	+323.16%	1.5TCr
EXELIXIS, INC.	+0.36%	+2.01%	+49.51%	+160.70%	1.45TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.91%	-3.51%	-4.56%	+517.49%	1.39TCr
Average	+0.44%	-1.52%	+37.83%	+170.87%	3.05TCr
Weighted average by Cap.	+0.35%	-1.91%	+38.58%	+128.16%